Next Article in Journal
Original Fluorescent Ligand-Based Assays Open New Perspectives in G-Protein Coupled Receptor Drug Screening
Next Article in Special Issue
Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics
Previous Article in Journal
Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2011, 4(1), 187-201;

L-Arginine Supplementation and Metabolism in Asthma

Pulmonary and Critical Care Medicine, University of California Davis, 451 Health Sciences Drive, GBSF, Rm. 6517, Davis, CA 95616, USA
Author to whom correspondence should be addressed.
Received: 4 November 2010 / Revised: 3 January 2011 / Accepted: 10 January 2011 / Published: 12 January 2011
(This article belongs to the Special Issue Genes, Mechanisms and Drugs for Asthma)
Full-Text   |   PDF [242 KB, uploaded 12 January 2011]


L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebo-controlled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10−3 vs. 1.1 ± 0.2 × 10−3 µmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 µmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10−1 vs. 2.6 ± 0.6 × 10−1 µmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study. View Full-Text
Keywords: asthma; L-arginine; nitric oxide; arginase; ADMA asthma; L-arginine; nitric oxide; arginase; ADMA
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Kenyon, N.J.; Last, M.; Bratt, J.M.; Kwan, V.W.; O’Roark, E.; Linderholm, A. L-Arginine Supplementation and Metabolism in Asthma. Pharmaceuticals 2011, 4, 187-201.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top